What are the nearest formulations of Combined Hormonal Contraceptives (CHCs) with lower doses of natural estradiol that may have less side effects to stop menstruation for one month?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Combined Hormonal Contraceptives for Temporary Menstrual Suppression

For temporary menstrual suppression for one month of travel, the vaginal ring (NuvaRing) is the optimal choice due to its lower estrogen dose (15 μg ethinyl estradiol), simple regimen, and excellent cycle control. 1

Recommended Options (from lowest to higher estrogen dose)

  • Vaginal Ring (NuvaRing) - First choice

    • Contains 15 μg ethinyl estradiol and 120 μg etonogestrel daily 1, 2
    • For menstrual suppression: insert a new ring immediately after removing the previous one (skip the ring-free week) 1
    • Advantages: lowest systemic estrogen exposure, simple to use, excellent cycle control 2, 3
    • High satisfaction rates (>90% of users satisfied) and easy to insert/remove 4
    • Common side effects: vaginal discharge, occasional discomfort, headache 2
  • Low-dose Combined Oral Contraceptives

    • Monophasic pills containing 20-30 μg ethinyl estradiol 1
    • For menstrual suppression: skip the placebo pills and start a new pack immediately 1
    • Advantages: widely available, can be started immediately 1
    • Common side effects: headache, nausea, breakthrough bleeding 1
  • Contraceptive Patch

    • Contains higher estrogen exposure (equivalent to 35 μg ethinyl estradiol) 1
    • For menstrual suppression: apply a new patch immediately after removing the third patch 1
    • Note: FDA has identified increased estrogen exposure (1.6 times higher than low-dose COCs) 1

Implementation Instructions

For NuvaRing (Recommended Option):

  1. Insert ring and leave in place for 3 weeks 1
  2. Instead of removing for a ring-free week, remove and immediately insert a new ring 1
  3. Continue this pattern until menstrual bleeding is desired again 1
  4. When ready to resume normal cycling, remove ring after 3 weeks and have a ring-free week 1

For Combined Oral Contraceptives:

  1. Take active pills continuously, skipping the placebo pills 1
  2. Start a new pack immediately after finishing the active pills in the current pack 1
  3. When ready to resume normal cycling, take a 7-day pill-free break after completing active pills 1

Clinical Considerations

  • Extended or continuous cycle regimens are particularly appropriate for temporary menstrual suppression for travel 1
  • The most common adverse effect of extended-cycle regimens is unscheduled breakthrough bleeding, which decreases over time 1
  • Eliminating the hormone-free interval optimizes ovarian suppression, potentially increasing contraceptive effectiveness 1
  • For patients not currently on hormonal contraception, start the method at least 7 days before travel to ensure adequate contraceptive coverage and assess initial tolerability 1

Important Caveats

  • If starting a new method, begin at least 7-10 days before travel to monitor for side effects 1
  • Breakthrough bleeding is more common when first using extended regimens but typically improves with continued use 1
  • If the patient has risk factors for venous thromboembolism, consider non-hormonal options instead 1
  • The vaginal ring can be removed for up to 3 hours if desired (though not typically recommended) 1
  • For patients who prefer pills, monophasic formulations are easier to use for extended cycles than multiphasic ones 1

By using the vaginal ring with its lower estrogen dose and simple administration, your patient can effectively suppress menstruation during travel while minimizing potential side effects 2, 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 2002

Research

The contraceptive vaginal ring.

Seminars in reproductive medicine, 2010

Research

High acceptability and satisfaction with NuvaRing use.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.